Senescence is a hallmark of aging, and senescent cells have a reputation to match. They are ‘zombie cells,’ sort of dead themselves but alive enough to poison their surroundings through senescence-associated secretory phenotype (SASP). The reality, though, is more complex. Read More
There is growing evidence of the role of soluble endoglin in the biology of platelets, including thrombosis. French researchers have investigated the role of genetic variants in the gene encoding endoglin, ENG, and the risk of venous thrombosis development. Read More
Oncopeptides AB has selected its first candidate drug based on the company’s unique platform for small polypeptide-based innate killer engagers (SPiKE). The SPiKE platform uses multispecific constructs, able to bind to multiple targets simultaneously. Read More
Resolution Therapeutics Ltd. has received approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study of its lead candidate RTX-001 in patients with decompensated liver cirrhosis. Read More
Signal transducer and activator of transcription 3 (STAT3) plays a key role in cell proliferation observed in colorectal cancer (CRC), where up-regulation of STAT3 accelerates tumorigenesis and promotes metastasis. Read More
Accutar Biotechnology Inc. has patented new substituted quinoline derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer. Read More
Monte Rosa Therapeutics Inc. has submitted an IND application to the FDA for MRT-6160, a highly selective and orally bioavailable molecular glue degrader directed against VAV1 in development for systemic and neurological autoimmune diseases. Read More
Aexon Labs Inc. has identified dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives acting as orexin receptors agonists. As such, they are reported to be possibly useful for the treatment of Parkinson’s disease, and type 1 and type 2 narcolepsy. Read More
Researchers at The Scripps Research Institute and the IAVI Neutralizing Antibody Center are developing a novel experimental vaccine targeting the germline to stimulate precursor B cells and produce broadly neutralizing antibodies (bnAbs) against the membrane-proximal external region (MPER) of the gp41 protein found in the HIV-1 envelope. Read More
Work at Shanghai Meiyue Biotech Development Co. Ltd. has led to the discovery of spiro-heterocycle substituted pyrimidine compounds acting as C-C chemokine receptor type 4 (CCR4) antagonists. Read More
Concerto Bioscience Inc. has received FDA clearance of its IND application to initiate a first-in-human phase I trial of Ensemble No.2 (ENS-002), an investigational live biotherapeutic product to treat atopic dermatitis. Read More
